The Mitogen Activated Protein Kinase (MAPK) pathway is one of the most commonly mutated signalling pathways in human cancers. While a range of small molecule inhibitors have been developed to inhibit the upstream and downstream effectors of this pathway, resistance remains a significant challenge.

After a successful first meeting in 2023, this next edition of the joint EACR and Boehringer Ingelheim virtual conference will focus on both the basic and clinical aspects of regulating signalling through the MAPK pathway and its role in cancer. A thorough understanding of the mechanisms of intrinsic and adaptive resistance is crucial for the development of more effective agents. The programme will include new insights on the mechanism of action of and resistance mechanisms to the new generation of pan-RAS inhibitors.

Register here